Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Isaac Bright
CEO
isaac.bright@rubryc.com

Message the company or request a 1:1 meeting here

RubrYc Therapeutics, Inc., is a biotechnology company applying proprietary machine-learning solutions to discover epitope-selective biologics. Inspired by recent advances in molecular library synthesis, massively parallel screening and computing, RubrYc is forging a new path for information-driven discovery of epitope-targeted drug candidates. RubrYc deploys our artificial intelligence and molecular engineering capabilities in the ELS System:

  1. Epitope: discover and develop Meso-scale Engineered Molecules (MEMs), our proprietary antigens that embody prescribed epitopes
  2. Library: design, produce, and select focused immune repertoires unique to each campaign (in vivo & in vitro)
  3. Screen: Phage to Mammalian display for high-affinity, high-expression, high-stability clones

RubrYc is a flexible and reliable discovery partner, accommodating multiple partnership models covering the span of biologics discovery activities. We thrive in two primary domains:

  1. Challenging targets and MoA – attacking the right epitope makes the ‘undruggable’ viable and valuable
  2. Bio-superior discovery – privileged epitope activity rapidly differentiates candidates vs. established benchmarks in well-characterized, accessible model system attacking the right epitope makes the “undruggable” viable and valuable B. Bio-superior discovery – privileged epitope activity rapidly differentiates candidates vs. established benchmarks in well-characterized, accessible model systems